During the last session, Protara Therapeutics Inc (NASDAQ:TARA)’s traded shares were 0.31 million, with the beta value of the company hitting 1.61. At the end of the trading day, the stock’s price was $4.53, reflecting an intraday loss of -3.82% or -$0.18. The 52-week high for the TARA share is $10.48, that puts it down -131.35 from that peak though still a striking 64.68% gain since the share price plummeted to a 52-week low of $1.60. The company’s market capitalization is $155.47M, and the average intraday trading volume over the past 10 days was 0.31 million shares, and the average trade volume was 2.41 million shares over the past three months.
Protara Therapeutics Inc (TARA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. TARA has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.54.
Protara Therapeutics Inc (NASDAQ:TARA) trade information
Protara Therapeutics Inc (TARA) registered a -3.82% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.82% in intraday trading to $4.53, hitting a weekly high. The stock’s 5-day price performance is -2.16%, and it has moved by -15.96% in 30 days. Based on these gigs, the overall price performance for the year is 131.12%. The short interest in Protara Therapeutics Inc (NASDAQ:TARA) is 2.74 million shares and it means that shorts have 14.46 day(s) to cover.
Protara Therapeutics Inc (TARA) estimates and forecasts
Statistics show that Protara Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Protara Therapeutics Inc (TARA) shares have gone up 95.26% during the last six months, with a year-to-date growth rate less than the industry average at 16.25% against 16.80.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 39.98%. While earnings are projected to return 7.10% in 2025, the next five years will return 15.23% per annum.
TARA Dividends
Protara Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Protara Therapeutics Inc (NASDAQ:TARA)’s Major holders
Protara Therapeutics Inc insiders own 6.13% of total outstanding shares while institutional holders control 51.11%, with the float percentage being 54.45%. OPALEYE MANAGEMENT INC. is the largest shareholder of the company, while 45.0 institutions own stock in it. As of 2024-06-30, the company held over 2.3 million shares (or 20.1758% of all shares), a total value of $5.3 million in shares.
The next largest institutional holding, with 1.9 million shares, is of RA CAPITAL MANAGEMENT, L.P.’s that is approximately 16.6361% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.95 million.
Also, the Mutual Funds coming in first place with the largest holdings of Protara Therapeutics Inc (TARA) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 616.3 shares. This amounts to just over 2.99 percent of the company’s overall shares, with a $2.79 million market value. The same data shows that the other fund manager holds slightly less at 140.67, or about 0.68% of the stock, which is worth about $0.64 million.
